All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How can venetoclax combinations improve outcome for FLT3-mutant AML?
How can venetoclax combinations improve outcome for FLT3-mutant AML?
Daver begins by outlining some of the successes seen in venetoclax therapies, discussing studies on venetoclax combinations such as VIALE-A and ADMIRAL. He goes on to discuss outcomes of venetoclax + gilteritinib combinations, with promising remission rates and molecular clearance rates.
How could new treatment options improve outcomes in FLT3-mutated AML?
During the 2022 ASCO Annual Meeting, the AML Hub spoke with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new treatment options improve outcomes in...
Editorial theme | An introduction to the use of transplantation for the treatment of AML
This article will look at the different stem cell sources used for HSCT, the patients selected for an HSCT, and the current major issues in the pre- and...
Subscribe to get the best content related to AML delivered to your inbox